いぼ治療薬の世界市場:パイプラインレビュー(2019上半期)

【英語タイトル】Warts - Pipeline Review, H1 2019

Global Markets Directが出版した調査資料(DATA906A406)・商品コード:DATA906A406
・発行会社(調査会社):Global Markets Direct
・発行日:2019年2月1日
・ページ数:101
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Enterprisewide(複数事業所内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Warts – Pipeline Review, H1 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Warts – Pipeline Review, H1 2019, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Warts – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 14, 3, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents
Introduction
Warts – Overview
Warts – Therapeutics Development
Warts – Therapeutics Assessment
Warts – Companies Involved in Therapeutics Development
Warts – Drug Profiles
Warts – Dormant Projects
Warts – Discontinued Products
Warts – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Warts, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Warts - Pipeline by Aclaris Therapeutics Inc, H1 2019
Warts - Pipeline by Cutanea Life Sciences Inc, H1 2019
Warts - Pipeline by Cytovation AS, H1 2019
Warts - Pipeline by G&E Corp, H1 2019
Warts - Pipeline by Genetic Immunity Inc, H1 2019
Warts - Pipeline by Laboratories Ojer Pharma SL, H1 2019
Warts - Pipeline by LEO Pharma A/S, H1 2019
Warts - Pipeline by Maruho Co Ltd, H1 2019
Warts - Pipeline by Nielsen Biosciences Inc, H1 2019
Warts - Pipeline by Novan Inc, H1 2019
Warts - Pipeline by Novartis AG, H1 2019
Warts - Pipeline by Pfizer Inc, H1 2019
Warts - Pipeline by Phio Pharmaceuticals Corp, H1 2019
Warts - Pipeline by Promius Pharma LLC, H1 2019
Warts - Pipeline by Tamir Biotechnology Inc, H1 2019
Warts - Pipeline by Verrica Pharmaceuticals Inc, H1 2019
Warts - Dormant Projects, H1 2019
Warts - Dormant Projects, H1 2019 (Contd..1), H1 2019
Warts - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Warts, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

【掲載企業】

Aclaris Therapeutics Inc、Cutanea Life Sciences Inc、Cytovation AS、G&E Corp、Genetic Immunity Inc、Laboratories Ojer Pharma SL、LEO Pharma A/S、Maruho Co Ltd、Nielsen Biosciences Inc、Novan Inc、Novartis AG、Pfizer Inc、Phio Pharmaceuticals Corp、Promius Pharma LLC、Tamir Biotechnology Inc、Verrica Pharmaceuticals Inc

★調査レポート[いぼ治療薬の世界市場:パイプラインレビュー(2019上半期)] (コード:DATA906A406)販売に関する免責事項を必ずご確認ください。
★調査レポート[いぼ治療薬の世界市場:パイプラインレビュー(2019上半期)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆